NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
McPheeters M, O’Connor EA, Riley S, et al. Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Nov. (Comparative Effectiveness Review, No. 262.)
Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review [Internet].
Show detailsKQ 1 and KQ 2
Table D-1. Acamprosate compared with placebo for Key Questions 1 and 2 (MS Word, 82K)
Table D-2. Disulfiram compared with control for Key Questions 1 and 2 (MS Word, 75K)
Table D-3. Naltrexone (any dose and delivery) compared with placebo for Key Questions 1 and 2 (MS Word, 89K)
Table D-4. Oral naltrexone (50 mg) compared with placebo for Key Questions 1 and 2 (MS Word, 75K)
Table D-5. Oral naltrexone (100 mg) compared with placebo for Key Questions 1 and 2 (MS Word, 75K)
Table D-6. Injectable naltrexone compared with placebo for Key Questions 1 and 2 (MS Word, 78K)
Table D-7. Baclofen compared with placebo for Key Questions 1 and 2 (MS Word, 79K)
Table D-8. Gabapentin compared with placebo for Key Questions 1 and 2 (MS Word, 75K)
Table D-9. Ondansetron compared with placebo for Key Questions 1 and 2 (MS Word, 75K)
Table D-10. Prazosin compared with placebo for Key Questions 1 and 2 (MS Word, 75K)
Table D-11. Topiramate compared with placebo for Key Questions 1 and 2 (MS Word, 79K)
Table D-12. Varenicline compared with placebo for Key Questions 1 and 2 (MS Word, 76K)
Table D-13. Acamprosate compared with disulfiram for Key Questions 1 and 2 (MS Word, 76K)
Table D-14. Acamprosate compared with naltrexone for Key Questions 1 and 2 (MS Word, 84K)
Table D-15. Disulfiram compared with naltrexone for Key Questions 1 and 2 (MS Word, 80K)
Table D-16. Topiramate compared with naltrexone for Key Questions 1 and 2 (MS Word, 76K)
KQ 3
Table D-17. Acamprosate compared with placebo for Key Question 3 (MS Word, 77K)
Table D-18. Disulfiram compared with placebo or control for Key Question 3 (MS Word, 80K)
Table D-19. Naltrexone compared with placebo for Key Question 3 (MS Word, 77K)
Table D-20. Baclofen compared with placebo for Key Question 3 (MS Word, 76K)
Table D-21. Gabapentin compared with placebo for Key Question 3 (MS Word, 77K)
Table D-22. Ondansetron compared with placebo for Key Question 3 (MS Word, 77K)
Table D-23. Prazosin compared with placebo for Key Question 3 (MS Word, 77K)
Table D-24. Topiramate compared with placebo for Key Question 3 (MS Word, 76K)
Table D-25. Varenicline compared with placebo for Key Question 3 (MS Word, 77K)
Table D-26. Acamprosate compared with disulfiram for Key Question 3 (MS Word, 82K)
Table D-27. Acamprosate compared with naltrexone for Key Question 3 (MS Word, 76K)
Table D-28. Disulfiram compared with naltrexone for Key Question 3 (MS Word, 78K)
- Strength-of-Evidence Assessments - Pharmacotherapy for Adults With Alcohol Use D...Strength-of-Evidence Assessments - Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review
- List of Acronyms/Abbreviations - Comparative Effectiveness and Safety of Oral Di...List of Acronyms/Abbreviations - Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes
- PREDICTED: Homo sapiens nudE neurodevelopment protein 1 (NDE1), transcript varia...PREDICTED: Homo sapiens nudE neurodevelopment protein 1 (NDE1), transcript variant X4, mRNAgi|2217306393|ref|XM_047434258.1|Nucleotide
- PREDICTED: Mus musculus septin 9 (Septin9), transcript variant X1, mRNAPREDICTED: Mus musculus septin 9 (Septin9), transcript variant X1, mRNAgi|1907082445|ref|XM_006533744.3|Nucleotide
- Introduction - Breast Reconstruction After Mastectomy: A Systematic Review and M...Introduction - Breast Reconstruction After Mastectomy: A Systematic Review and Meta-Analysis
Your browsing activity is empty.
Activity recording is turned off.
See more...